Kiora Q3 10-Q: Going-Concern Warning, $6.2M Nine-Month Loss, KIO-104 Shelved
KPRX is trading near its 52-week low of $1.33 (5.3% above the low).
Summary
Kiora's Q3 2026 10-Q shows a $1.75M quarterly net loss, cash down to $5.57M, and an explicit going-concern warning, offset by $1.0M of CKD collaboration revenue and the October pivot to KIO-401 with KIO-104 discontinued.
Key Events · Earnings and Guidance · KPRX
-
Going-Concern Warning Disclosed
Management states substantial doubt about the Company's ability to continue as a going concern, with cash and short-term investments of $5.6 million and $10.7 million at September 30, 2026 funding operations only into late 2027, excluding the technology transfer milestone.
-
Q3 Loss Widens, Cash Burns Down
Net loss was $1.75 million for Q3 2026 versus $26,806 of net income a year earlier; nine-month net loss reached $6.25 million versus $4.32 million. Cash and equivalents fell to $5.57 million from $8.70 million at December 31, 2025.
-
KIO-104 Discontinued, Impairment Ahead
In October 2026 Kiora discontinued KIO-104 development, not for safety or efficacy reasons. It will test the $1.0 million in-process R&D asset for impairment in Q4 2026 and may reverse up to $1.7 million of contingent consideration liabilities.
-
CKD Deal Books $1.0M Revenue
The August 2026 Chong Kun Dang license for KIO-301 in Korea generated $1.0 million of collaboration revenue in Q3 2026, net of $165,000 Korean withholding tax, with up to $15.5 million in milestones plus 10% royalties still eligible.
Analysis · KPRX · Life Sciences
Kiora's balance sheet is thinner than it looks. Cash and equivalents dropped to $5.57M from $8.70M at year-end, and total liquidity of roughly $16.3M ($5.57M cash plus $10.72M short-term investments) is now committed against a $3.5M Senju upfront payment plus a $12.5M technology transfer milestone that may come due before the stated late-2027 runway. Management explicitly states substantial doubt about the ability to continue as a going concern, so another raise is close to certain — and the April 2026 private placement already added 438,471 shares plus warrants for up to 11.36M more shares. The offsetting positive is that the pivot to KIO-401 is real: the CKD deal booked $1.0M of collaboration revenue in Q3, and discontinuing KIO-104 frees cash and could reverse up to $1.7M of contingent consideration. The near-term mechanical risk is the Tranche A-1 warrants: 7,864,726 shares at $1.94 expire November 28, 2026 unless exercised, and with the stock at $1.40 they are far out of the money — a large chunk of potential financing that will likely vanish.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPRX was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $1.33 to $2.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.